Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia.
Anticoagulation
Antiplatelet therapy
Atrial fibrillation
Cancer
Thrombocytopenia
Venous thromboembolism
Journal
Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
16
09
2019
revised:
23
12
2019
accepted:
03
01
2020
entrez:
2
8
2020
pubmed:
2
8
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
A B S T R A C T Antithrombotic therapy (anticoagulation or antiplatelet therapy) is frequently prescribed in cancer patients for prior or new indications such as venous thromboembolism, secondary prevention of arterial thrombosis or atrial fibrillation. Therefore, it is not uncommon for thrombocytopenic cancer patients to have an indication for antithrombotic therapy. Thrombocytopenia does not reduce the risk of recurrent thrombosis. The bleeding risk with anticoagulation appears to increase when platelets are <50×10
Identifiants
pubmed: 32736782
pii: S0049-3848(20)30400-X
doi: 10.1016/S0049-3848(20)30400-X
pii:
doi:
Substances chimiques
Anticoagulants
0
Platelet Aggregation Inhibitors
0
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S68-S73Informations de copyright
© 2020 Elsevier Ltd. All rights reserved.